Litigation Details for In Re: MYLAN N v. SECURITIES LITIGATION (S.D.N.Y. 2016)
✉ Email this page to a colleague
In Re: MYLAN N v. SECURITIES LITIGATION (S.D.N.Y. 2016)
Docket | ⤷ Sign Up | Date Filed | 2016-10-11 |
Court | District Court, S.D. New York | Date Terminated | |
Cause | 15:78m(a) Securities Exchange Act | Assigned To | James Paul Oetken |
Jury Demand | Plaintiff | Referred To | |
Patents | 7,449,012 | ||
Link to Docket | External link to docket |
Small Molecule Drugs cited in In Re: MYLAN N v. SECURITIES LITIGATION
Details for In Re: MYLAN N v. SECURITIES LITIGATION (S.D.N.Y. 2016)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
2017-03-20 | 39 | Amended Complaint | expiration of U.S. Patent Nos. 7,449,012 B2 (the “‘012 patent”) and 7,794,432 B2 (the “‘432 patent”), which expire…Numbers 7,449,012, 7,794,432, 8,048,035, and 8,870,827 (the “EpiPen Patents”). These four patents have a …settling its patent infringement suit against Teva Pharmaceuticals (“Teva”) relating to the patents covering…additional patents for features that were subsequently integrated into the EpiPen: U.S. Patent Numbers…The issuance of the EpiPen Patents, and Mylan’s designation of these patents as covering the EpiPen, | External link to document |
2017-05-30 | 45 | Consolidated Amended Complaint | expiration of U.S. Patent Nos. 7,449,012 B2 (the “‘012 patent”) and 7,794,432 B2 (the “‘432 patent”), which expire…Numbers 7,449,012, 7,794,432, 8,048,035, and 8,870,827 (the “EpiPen Patents”). These four patents have a …settling its patent infringement suit against Teva Pharmaceuticals (“Teva”) relating to the patents covering…additional patents for features that were subsequently integrated into the EpiPen: U.S. Patent Numbers…The issuance of the EpiPen Patents, and Mylan’s designation of these patents as covering the EpiPen, | External link to document |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |